HOME > Products and Technologies > Clinical Trials
Biologics
VM202-DPN
Neovascularization & neurogenesis therapy for diabetic peripheral neuropathy
Phase III Ongoing US Clinicaltrials.gov - NCT02427464
Phase II Completed US, Korea Clinicaltrials.gov - NCT01475786
Phase I Completed US Clinicaltrials.gov - NCT01002235
  (In Korea Market: Reyon Pharmaceutical Co., Ltd.)
 
VM202-PAD
Angiogenic therapy for Chronic non-healing ischemic foot ulcer in diabetes / critical limb ischemia
Phase III Ongoing US Clinicaltrials.gov - NCT02563522
Phase II Completed US, Korea Clinicaltrials.gov - NCT01064440
Phase II Completed China Clinicaltrials.gov - NCT01548378
Phase I Completed US Clinicaltrials.gov - NCT00696124
Phase I Completed China  
  (In Korea market: Reyon Pharmaceutical Co., Ltd.)
 
VM501
Chemotherapy Induced Thrombocytopenia - Recombinant IL-11 for chemotherapy-induced thrombocytopenia
Phase III Ongoing China
Phase IIb Completed China
Phase IIa Completed China
  (Partner: Beijing Northland Biotech)
 
VM202-ALS
Neovascularization & neurogenesis therapy for amyotrophic lateral sclerosis
Phase I/II Completed US Clinicaltrials.gov - NCT02039401
  (Joint developer: Reyon Pharmaceutical Co., Ltd.)
 
VM202-CAD
Angiogenic therapy for ischemic heart failure
Phase II Ongoing Korea  
  (Partner in Korea: Reyon Pharmaceutical Co., Ltd.)
VM202 as an adjunct therapy during CABG for ischemic heart disease
Phase I Completed Korea Clinicaltrials.gov - NCT01422772
  (Partner in Korea: Reyon Pharmaceutical Co., Ltd.)
 
VM206
Breast Cancer - DNA drug that instructs the body to produce antibody & CTL specific to Her2
Phase I Completed Korea Clinicaltrials.gov - NCT01895491
  (Partner in Asia(excluding Japan): Reyon Pharmaceutical Co., Ltd.)